Elena Ridloff, CFA, senior vice president, Investor Relations will serve as the company's Interim chief financial officer.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
The company has developed and is commercialising the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder and Rett syndrome.
Nuplazid is the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.
It is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson's disease psychosis.
Nuplazid is an oral medicine taken once a day with a recommended dose of 34 mg. Acadia discovered and developed this new chemical entity and holds worldwide rights to develop and commercialise Nuplazid.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials